Research programme: gene therapies - Roche Madison
Latest Information Update: 16 Jul 2016
Price :
$50 *
At a glance
- Originator Mirus Bio Corporation
- Developer Roche Madison
- Class Gene therapies
- Mechanism of Action Angiogenesis inducing agents; Erythropoiesis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Anaemia; Peripheral ischaemia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Anaemia in USA (Parenteral, Injection)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Peripheral-ischaemia in USA (Parenteral)
- 24 Oct 2011 Roche Madison has been acquired by Arrowhead Research Corporation